DexCom (NASDAQ:DXCM) Receives Hold (C-) Rating from Weiss Ratings

Key Points

• DexCom received a "hold (C-)" rating from Weiss Ratings, indicating potential concerns about the stock's performance.
• Despite the hold rating, other brokerages have favorable views, with three analysts issuing "Strong Buy" ratings and a target price consensus of $97.42.
• The company's stock price reached $67.78, with a 12-month trading range between $57.52 and $93.25, reflecting volatility in market performance.

DexCom (NASDAQ:DXCM - Get Free Report)'s stock had its "hold (c-)" rating reaffirmed by equities researchers at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

A number of other brokerages also recently weighed in on DXCM. Argus began coverage on DexCom in a research note on Thursday, August 21st. They issued a "buy" rating and a $100.00 target price on the stock. Raymond James Financial upped their price objective on DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 31st. Oppenheimer downgraded DexCom from an "outperform" rating to a "market perform" rating in a research note on Monday, September 8th. William Blair upgraded DexCom to a "strong-buy" rating in a research note on Thursday, July 31st. Finally, Piper Sandler upped their price objective on DexCom from $90.00 to $100.00 and gave the company an "overweight" rating in a research note on Thursday, July 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $97.42.

DexCom Stock Performance

Shares of NASDAQ DXCM traded up $1.75 during midday trading on Wednesday, reaching $67.78. The company's stock had a trading volume of 5,945,567 shares, compared to its average volume of 6,727,868. DexCom has a 12-month low of $57.52 and a 12-month high of $93.25. The firm has a 50 day moving average price of $74.96 and a 200-day moving average price of $77.73. The stock has a market capitalization of $26.58 billion, a P/E ratio of 47.07, a PEG ratio of 1.38 and a beta of 1.47. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the previous year, the business earned $0.43 EPS. The company's revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, equities analysts predict that DexCom will post 2.03 earnings per share for the current year.

Insider Buying and Selling

In other DexCom news, Director Kyle Malady sold 667 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the sale, the director owned 22,667 shares in the company, valued at $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director owned 51,121 shares in the company, valued at approximately $4,143,868.26. This represents a 5.10% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,849 shares of company stock worth $564,733. Insiders own 0.32% of the company's stock.

Institutional Investors Weigh In On DexCom

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Czech National Bank raised its position in shares of DexCom by 3.9% in the third quarter. Czech National Bank now owns 99,600 shares of the medical device company's stock worth $6,702,000 after buying an additional 3,755 shares in the last quarter. Sendero Wealth Management LLC raised its position in shares of DexCom by 85.6% in the third quarter. Sendero Wealth Management LLC now owns 67,423 shares of the medical device company's stock worth $4,537,000 after buying an additional 31,094 shares in the last quarter. Cullen Investment Group LTD. raised its position in shares of DexCom by 6.5% in the third quarter. Cullen Investment Group LTD. now owns 15,164 shares of the medical device company's stock worth $1,017,000 after buying an additional 927 shares in the last quarter. Union Bancaire Privee UBP SA raised its position in shares of DexCom by 129.6% in the third quarter. Union Bancaire Privee UBP SA now owns 5,464 shares of the medical device company's stock worth $346,000 after buying an additional 3,084 shares in the last quarter. Finally, Sanders Morris Harris LLC purchased a new stake in shares of DexCom in the third quarter worth $269,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.